Effects of ipragliflozin on body composition and beta-cell function in Japanese patients with type 2 diabetes

Effects of ipragliflozin on body composition and beta-cell function in Japanese patients with type 2 diabetes - Effects of ipragliflozin on body composition and beta-cell function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021623

Enrollment

Registered

2016-03-27

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

ipraglifrozin 50mg/day for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients HbA1c >= 6.5% 20 <= BMI <= 40

Exclusion criteria

Exclusion criteria: The exclusion criteria were pregnancy, severe illness, CKD (eGFR < 60 ml/min/1.73m2), and malignancy.

Design outcomes

Primary

Measure	Time frame
%Change of visceral fat volume assessed by CT and %change of intrahepatic lipid content assessed by 1H-MRS at 0-, 12- and 24-week of ipraglifrozin treatment	—

Secondary

Measure	Time frame
beta-cell stress assessed by the change of plasma intact proinsulin / C-peptide (PI/CPR) ratio at 0-, 12- and 24-week of ipraglifrozin treatment	—

Countries

Japan

Contacts

Public ContactYoshio Nagai

St. Marianna University School of Medicine Division of Metabolism and Endocrinology, Department of Internal Medicine

ynagai@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026